2021 Year in Review - Ovarian Cancer
Phase 3b OPINION Primary Analysis of Olaparib Maintenance Monotherapy for Nongermline BRCA1/2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
Final Overall Survival Results from the LIGHT Study of Olaparib Treatment in Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status
The final overall survival analysis of the phase 2 LIGHT study indicates that olaparib therapy in patients with platinum-sensitive relapsed ovarian cancer provides overall survival benefit across patient cohorts, regardless of BRCA mutation and homologous recombination deficiency status, with a safety profile consistent with that previously described.
Analysis of the Phase 3 PAOLA-1/ENGOT-ov25 Trial by Disease Stage in Patients with Homologous Recombination Deficiency–Positive Newly Diagnosed Advanced Ovarian Cancer Receiving Bevacizumab with Olaparib/Placebo Maintenance
Results of the PAOLA-1/ENGOT-ov25 study demonstrated sustained progression-free survival benefit with the addition of maintenance olaparib to bevacizumab, compared with placebo and bevacizumab in homologous recombination deficiency-positive patients, irrespective of International Federation of Gynecology and Obstetrics stage and residual disease after up-front surgery.
Subgroup Analysis of the ARIEL4 Study of the Effect of Platinum Sensitivity on Efficacy of Rucaparib versus Chemotherapy for BRCA-Mutated, Advanced, Relapsed Ovarian Carcinoma
Results of the subgroup analysis of the ARIEL4 study suggest that heavily pretreated patients with advanced relapsed ovarian carcinoma harboring a BRCA1/2 mutation derive progression-free survival benefit from rucaparib treatment across all platinum-sensitivity subgroups.
5-Year Follow-Up of the SOLO1/GOG 3004 Trial of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation
Five-year follow-up results of the SOLO1 trial indicate that 2 years of maintenance olaparib provides sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer harboring BRCA1 and/or BRCA2 mutations, with no emergence of new safety signals.
Olaparib Treatment in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Secondary Safety Results from the Phase 2 LIGHT Study
Progression-Free Survival Benefit from Maintenance Olaparib in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA and Other Homologous Recombination Repair Gene Mutation Status (ORZORA Trial)
ARIEL4 Results of Rucaparib versus Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation
Results of the phase 3, randomized ARIEL4 trial demonstrate that patients with BRCA-mutated advanced, relapsed ovarian cancer derive significant progression-free survival benefit from rucaparib therapy compared with standard-of-care chemotherapy, with the emergence of no new safety signals.
Page 1 of 3
Results 1 - 10 of 30
Results 1 - 10 of 30